Grantham, Mayo, Van Otterloo & Co (GMO)’s Vertex Pharmaceuticals VRTX Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-58,506	Closed	-$20.6M	–	695
2023 Q2	$20.6M	Sell	58,506 -37,394	-39%	-$12.6M	0.1%	179
2023 Q1	$30.2M	Sell	95,900 -21,300	-18%	-$6.39M	0.15%	140
2022 Q4	$33.8M	Buy	117,200 +4,200	+4%	+$1.28M	0.18%	121
2022 Q3	$32.7M	Sell	113,000 -500	-0.4%	-$144K	0.19%	106
2022 Q2	$32M	Buy	113,500 +31,400	+38%	+$8.4M	0.17%	112
2022 Q1	$21.4M	Buy	+82,100	New	+$19.5M	0.1%	177
2019 Q2	–	Sell	-3,200	Closed	-$589K	–	779
2019 Q1	$589K	Hold	3,200	–	–	﹤0.01%	562
2018 Q4	$530K	Buy	+3,200	New	+$554K	﹤0.01%	429
2017 Q1	–	Sell	-100,000	Closed	-$7.37M	–	649
2016 Q4	$7.37M	Buy	100,000 +49,700	+99%	+$4.04M	0.04%	216
2016 Q3	$4.39M	Buy	+50,300	New	+$4.75M	0.02%	259

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s VRTX Position: Q3 2023 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 58,506 shares — an estimated $20.6M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in VRTX in Q3 2016 and held it in 10 quarters. The position peaked at $33.8M in Q4 2022. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Grantham, Mayo, Van Otterloo & Co (GMO) sold 58,506 Vertex Pharmaceuticals shares in Q3 2023, an estimated $20.6M.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Vertex Pharmaceuticals in Q3 2016 and held it in 10 quarters.
Grantham, Mayo, Van Otterloo & Co (GMO)'s Vertex Pharmaceuticals position peaked at $33.8M in Q4 2022.
1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q3 2023, filed 13 Nov 2023.